Welcome to ACCESS DMD, the Marathon Expanded Access Program

Thank you for your interest in ACCESS DMD. MP-104-CL-037 is an open label, expanded access protocol intended to provide treatment with MP-104 (deflazacort) to children, adolescents, and/or adults with Duchenne muscular dystrophy, in the United States. ACCESS DMD is sponsored by Marathon Pharmaceuticals, LLC. The program will be completed according to the guidelines of Good Clinical Practice.



Registration

FOR HEALTHCARE PROVIDERS ONLY
If you are a Health Care Provider and want to register for ACCESS DMD please use the Register button below.

Already Registered?